Imagenetix, Inc. (OTCBB: IAGX), www.imagenetix.net, the developer of Celadrin(R), a proprietary fatty acid complex useful in promoting joint health, announced today that it has formed a partnership with Cymbiotics, Inc., a San Diego, Calif.-based company, and Dr. Reddy's Laboratories (NYSE: RDY), a major pharmaceutical company in Hyderabad, India, to launch Celadrin to physicians treating patients with osteoarthritis in India. Celadrin has been approved for use as a pharmaceutical product in India to help reduce pain and inflammation in patients with joint conditions. In the United States, Celadrin is currently available in oral form as a dietary supplement and as an over-the-counter topical cream at food, drug and mass retail stores.
Bill Spencer, CEO of Imagenetix, said: "Celadrin is a proprietary fatty acid complex that has been clinically shown to promote joint health with no known or reported side effects. We are pleased that Dr. Reddy's, a public traded New York Stock Exchange company, is introducing Celadrin to doctors and consumers throughout India."
According to Satish Reddy, Managing Director and COO of Dr. Reddy's: "Dr. Reddy's is emerging as the partner of choice for many innovators in healthcare because of our strong brand equity and extensive reach in the Indian market. Celadrin will enhance the treatment options available to medical practitioners in India, and we will be marketing the product in capsule and topical cream forms."
Celadrin has been shown to be safe and effective in several double-blind, placebo-controlled clinical studies. In one such study conducted at the University of Connecticut, subjects with knee joint conditions who used Celadrin in cream form showed significant improvement in quality of life measurements such as getting up from a seated position and stair climbing. A similar study determined that patients who took Celadrin orally improved knee range of motion and overall function. Both studies were published in the prestigious Journal of Rheumatology. Participants in the studies exhibited no side effects.
San Diego-based Imagenetix, Inc. (Symbol: IAGX), www.imagenetix.net, is an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health. The company develops, formulates and private-labels, proprietary over-the-counter topical creams, skin care products, nutritional supplements and pharmaceutical compounds to be marketed globally through multiple channels of distribution.
About Dr. Reddy's
Dr. Reddy's Laboratories (NYSE: RDY), www.drreddys.com, is a global, vertically integrated pharmaceutical company with a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed in more than 100 countries.
Cymbiotics, Inc., based in San Diego, Calif. (USA), is a bio-pharmaceutical company that designs, develops, validates and introduces innovative disease-specific formulations in pain management, cardiovascular disease, periodontal disease, urinary incontinence and other inflammation management-related conditions. For more information, visit www.cymbiotics.net.